Mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy-Reference-Cited by-同舟云学术

Mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy

Published:2020-09-18 Issue:6 Volume:7 Page:3983-3995
ISSN:2055-5822
Container-title:ESC Heart Failure
language:en
Short-container-title:ESC Heart Failure

Author:

Lowe Jeovanna¹,Kolkhof Peter²^ORCID,Haupt Michael J.¹,Peczkowski Kyra K.¹,Rastogi Neha¹,Hauck J. Spencer¹,Kadakia Feni K.¹,Zins Jonathan G.¹,Ciccone Pierce C.¹,Smart Suzanne³,Sandner Peter²⁴,Raman Subha V.³,Janssen Paul M.L.¹,Rafael‐Fortney Jill A.¹^ORCID

Affiliation:

1. Department of Physiology and Cell Biology, College of Medicine The Ohio State University Columbus OH 43210 USA

2. R&D Preclinical Research Cardiovascular Bayer AG Wuppertal Germany

3. Davis Heart and Lung Research Institute, College of Medicine The Ohio State University Columbus OH 43210 USA

4. Department of Pharmacology Hannover Medical School Hannover Germany

Funder

Bayer

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link